Circulating molecules in blood may be stepping stone for type 1 diabetes early prediction

September 19, 2019

Researchers from the Turku Bioscience Centre in Finland have found changes in molecules in the blood that might be new markers of type 1 diabetes. New findings may help understand the early pathogenesis of the disease.

Finland has the highest recorded incidence of type 1 diabetes in children younger than 15 years, and the global prevalence is continuously increasing among the children in many developed countries.

Using state-of-the-art metabolomics approach, researchers from the Turku Bioscience Centre, a joint unit of the University of Turku and Åbo Akademi University, found changes in circulating molecules in the blood, i.e. metabolites, already before the initiation of islet autoimmunity. The findings may have important implications in the search of early markers of type 1 diabetes and for understanding the disease pathogenesis.

The study was part of the extensive Finnish DIPP cohort study.

Early Prediction of Type 1 Diabetes May Be Feasible

In current preclinical settings, the appearance of islet autoantibody is the first detectable signal implicating the initiation of autoimmunity and risk of progression towards diabetes. However, although autoantibody positivity precedes the clinical disease by months to years, the time point at which autoantibody appears may already be too late for therapeutic approaches aimed at preventing progression to overt diabetes.

"Thus, our current and previous metabolomics-based findings suggest that early prediction of type 1 diabetes may be feasible, providing an extended window of opportunity for the interventions for disease prevention," says Group Leader at the Turku Bioscience Centre Matej Orešič.

The research group is working on validating their current and previous findings in a more extensive and more heterogeneous cohort study in collaboration with Professor Mikael Knip from the University of Helsinki.

"Our future objective is to provide new insights into type 1 diabetes disease pathogenesis through improved understanding of the metabolic and immune system interplay, which would be an important stepping stone for the early prediction as well as prevention of the disease," Orešič summarises.
-end-
Information of the publication: Lamichhane S, Kemppainen E, Trošt K, Siljander H, Hyöty H, Ilonen J, Toppari J, Veijola R, Hyötyläinen T, Knip M, Orešič M: Circulating metabolites in progression to islet autoimmunity and type 1 diabetes. Diabetologia 2019. https://doi.org/10.1007/s00125-019-04980-0https://doi.org/10.1007/s00125-019-04980-0

More information: Matej Orešič, Turku Bioscience Centre, University of Turku and Åbo Akademi University, +358 44 972 6094, matej.oresic@utu.fi

University of Turku

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.